Skip to main content

Table 2 Outcomes reported by included studies

From: Prothrombin complex concentrate (PCC) for treatment of trauma-induced coagulopathy: systematic review and meta-analyses

Studies references

In-hospital

Mortality

DVT

In hosp

RBC (unit)

Platelets (unit)

FFP

(unit)

Other outcomes reported

Jehan

[26]

PCC + FFP: 10 (25)

FFP 26 (33)

p = 0.04*

PCC + FFP: 1 (2.5)

FFP: 1 (1.2)

p = 0.51*

Unclear

PCC + FFP: 7 (3)µ

FFP: 9 (5)µ

p < 0.04*

Unclear

PCC + FFP: 3 (3)µ

FFP: 3 (3)µ

p = 0.72*

Unclear

PCC + FFP: 5 (2)µ

FFP: 7 (3)µ

p = 0.03*

Proportion of patients with INR correction and time to INR correction from admission*

Rate of correction of INR*

Other TE*: PE, Mesenteric ischemia

ICU and Hospital LOS

Joseph

[31]

PCC + FFP: 15 (23)

FFP alone: 53 (28)

p = 0.04

PCC + FFP: 1 (1.6)

FFP alone: 2 (1.1)

p = 0.6*

Total

PCC + FFP: 6.6 (4.1)µ

FFP alone: 10 (8.3)µ

p = 0.001*

Total

PCC + FFP: 1.2 (2.1)µ

FFP alone: 1.5 (2.7)µ

p = 0.2*

Total

PCC + FFP: 2.8 (1.8)µ

FFP alone: 3.9 (1.3)µ

p = 0.01*

Proportion of patients with INR correction and time to INR correction from admission*

Time to treatment*

Mesenteric infarction*

ICU and Hospital LOS

Costs: therapy*, transfusion*, hospital

Joseph

[24]

PCC: 6 (22.3)

FFP 15 (27.8)

p = 0.78

PCC: 3 (11.1)

FFP: 4 (7.4)

p = 0.68*

Total

PCC: 3.2 (1.9)µ

FFP: 5.4 (4.1)µ

p = 0.009*

Total

PCC: 1.4 (2.3)µ

FFP: 1.6 (2.4)µ

p = 0.72*

Total

PCC: 5.1 (3.6)µ

FFP: 90.7 (4.1)µ

p = 0.005*

Proportion of patients with INR correction and time to INR correction from admission*

Time to treatment

Time to surgery

Mesenteric or myocardial infarction

ICU and Hospital LOS

Costs: therapy, transfusion, hospital, charges

Khurrum

[27]

PCC + WB: 39 (46)

WB 74 (44)

p = 0.72*

PCC + WB: 3 (4)

WB: 8 (5)

p = 0.75

At 24 h

PCC + WB: 8 (5–14)$

WB: 10 (6–18)$

p = 0.04*

At 24 h

PCC + WB: 2 (1–3)$

WB: 2 (1–4)$

p = 0.19*

At 24 h

PCC + WB: 6 (4–10)$

WB: 8 (4–12)$

p = 0.01*

PCC units

In ED mortality

ED, ICU and hospital LOS

AKI, ARDS, PE

Ponschab

[30]

–

–

At 24 h

All patients: 7 (3–10) [7]

At 24 h

All patients: 0 (0–00) [7]

At 24 h

All patients: 0 (0–0)7

ROTEM parameter

PCC unit, FC (g) and TXA (g) administrated at 24 h

Schlimp

[28]

PCC + FC: 18 (29)

FC: 7 (8)

PCC + FC + FFP: 5 (56)

p < 0.0001

–

At 24 h

PCC + FC: 8 (5–11)$

FC: 3 (2–6)$

PCC + FC + FFP: 21 (18–26)$

p < 0.0001

At 24 h

PCC + FC: 0 (0–0)$

FC: 0 (0–0)$

PCC + FC + FFP: 4 (2–4)$

p < 0.001

At 24 h

PCC + FC: none

FC: none

PCC + FC + FFP: 6 (6–10)$

p = NA

Transfusion (RBC, FFP, platelet, FC, PCC) volume in ED and ICU

Massive transfusion

Standard and specific coagulation tests including ROTEM over 7 days

Schöchl

[29]

PCC + FC: 0 (0)

FC: 0 (0)

NCT: 0 (0)

-

At 24 h

PCC + FC: 8 (6–10.5)$

FC: 3 (0–5)$

NCT: 0 (0–2)$

p < 0.001

At 24 h

PCC + FC: 0 (0–1)$

FC: 0 (0–0)$

NCT: 0 (0–0)$

p < 0.001

At 24 h

PCC + FC: 0 (0–0)$

FC: 0 (0–0)$

NCT: 0 (0–0)$

p = ns

PCC and FC unit transfused

Standard and specific coagulation tests including ROTEM over 7 days

Zeeshan

[25]

4F-PCC: 32 (26)

3F-PCC: 35 (28)

p = 0.78*

4F-PCC: 2 (1.4)

3F-PCC: 3 (2.1)

p = 0.81*

Total

4F-PCC: 7 (2)µ

3F-PCC: 10 (3)µ

p = 0.04*

Total

4F-PCC: 3 (3)µ

3F-PCC: 3 (3)µ

p = 0.23*

Total

4F-PCC: 6 (2)µ

3F-PCC: 8 (2)µ

p = 0.03*

Proportion of patients with INR correction and time to INR correction from admission*

ICU and Hospital LOS

Other TE*: Mesenteric infarction, PE

Costs: therapy, transfusion, total hospital

Zeeshan 2018

[26]

4-PCC + FFP: 41 (17.5)

FFP: 65 (27.7)

p = 0.01*

PCC + FFP: 8 (3.4)

FFP: 13 (5.5)

p = 0.11

At 24 h

PCC + FFP: 6 (4)µ

FFP: 10 (4)µ

p = 0.02*

At 24 h

PCC + FFP: 3 (2)µ

FFP: 3 (3)µ

p = 0.72*

At 24 h

PCC + FFP: 3 (2)µ

FFP: 6 (3)µ

p = 0.01*

ED mortality*

Transfusion at 4 h*

ICU and Hospital LOS

Skilled nursing facility or rehab. disposition

Complications: AKI, ARDS, PE

  1. * Continuous variables are presented either as median (IQR) % or as mean (SD)#; categorical variables are presented as number and relative percentages. Number of patients or relative percentages were calculated if not reported. * Reported as primary outcome(s). Some variables are presented after PS matching& while others are presented before PS matching!. £ Protocol doses are unknown; ^Unknown type of PCC. AKI Acute Kidney Injury, ARDS acute respiratory distress syndrome, ED emergency department, FC fibrinogen concentrate, ICU intensive care unit, ISS injury severity score, INR international normalized ratio, LOS length of stay, PE pulmonary embolism, PCC prothrombin complex concentrate, PS propensity score, TXA tranexamic acid, US United States